A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model

ABSTRACT
The emergence of SARS-CoV-2 led to pandemic spread of coronavirus disease 2019 (COVID-19), manifesting with respiratory symptoms and multi-organ dysfunction. Detailed characterization of virus-neutralizing antibodies and target epitopes is needed to understand COVID-19 pathophysiology and guide immunization strategies. Among 598 human monoclonal antibodies (mAbs) from ten COVID-19 patients, we identified 40 strongly neutralizing mAbs. The most potent mAb CV07-209 neutralized authentic SARS-CoV-2 with IC50 of 3.1 ng/ml. Crystal structures of two mAbs in complex with the SARS-CoV-2 receptor-binding domain at 2.55 and 2.70 Å revealed a direct block of ACE2 attachment. Interestingly, some of the near-germline SARS-CoV-2 neutralizing mAbs reacted with mammalian self-antigens. Prophylactic and therapeutic application of CV07-209 protected hamsters from SARS-CoV-2 infection, weight loss and lung pathology. Our results show that non-self-reactive virus-neutralizing mAbs elicited during SARS-CoV-2 infection are a promising therapeutic strategy.
Competing Interest Statement
Related to this work the German Center for Neurodegenerative Diseases (DZNE) and the Charite - Universitaetsmedizin have filed a patent application on which JK, SMR, HCK, ESS, VMC, MAM, DW, LES and HP are named as inventors.
Subject Area
- Biochemistry (9101)
- Bioengineering (6749)
- Bioinformatics (23935)
- Biophysics (12086)
- Cancer Biology (9491)
- Cell Biology (13728)
- Clinical Trials (138)
- Developmental Biology (7614)
- Ecology (11656)
- Epidemiology (2066)
- Evolutionary Biology (15476)
- Genetics (10615)
- Genomics (14292)
- Immunology (9456)
- Microbiology (22773)
- Molecular Biology (9069)
- Neuroscience (48840)
- Paleontology (354)
- Pathology (1479)
- Pharmacology and Toxicology (2562)
- Physiology (3822)
- Plant Biology (8307)
- Synthetic Biology (2289)
- Systems Biology (6169)
- Zoology (1297)